The Asia Pacific Circulating Tumor Cell Market is expected to witness market growth of 13.6% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Circulating Tumor Cell Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $3.16 billion by 2031. The Japan market is registering a CAGR of 13.1% during 2024-2031. Additionally, the India market is expected to showcase a CAGR of 14.4% during 2024-2031.
The circulating tumor cell market has emerged as a rapidly growing segment within the global cancer diagnostics and treatment industry. Circulating tumor cell (CTCs) are cancer cells that detach from the primary tumor and circulate in the bloodstream, making them a valuable source for non-invasive cancer diagnosis, monitoring, and personalized treatment strategies.
Additionally, these cells are often the precursors to metastasis, the process by which cancer spreads to other body parts. The ability to detect and analyze CTCs provides crucial information about cancer progression, allowing for early detection, real-time monitoring, and the identification of therapeutic targets.
The growing healthcare infrastructure and increasing cancer cases in India and China drive the circulating tumor cell market. CTCs, critical for non-invasive cancer detection and monitoring, are gaining attention as vital diagnostic tools in oncology. As these countries ramp up their healthcare investments and address the rising cancer burden, the market is poised for substantial growth in both regions.
The China market dominated the Asia Pacific Circulating Tumor Cell Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $3.16 billion by 2031. The Japan market is registering a CAGR of 13.1% during 2024-2031. Additionally, the India market is expected to showcase a CAGR of 14.4% during 2024-2031.
The circulating tumor cell market has emerged as a rapidly growing segment within the global cancer diagnostics and treatment industry. Circulating tumor cell (CTCs) are cancer cells that detach from the primary tumor and circulate in the bloodstream, making them a valuable source for non-invasive cancer diagnosis, monitoring, and personalized treatment strategies.
Additionally, these cells are often the precursors to metastasis, the process by which cancer spreads to other body parts. The ability to detect and analyze CTCs provides crucial information about cancer progression, allowing for early detection, real-time monitoring, and the identification of therapeutic targets.
The growing healthcare infrastructure and increasing cancer cases in India and China drive the circulating tumor cell market. CTCs, critical for non-invasive cancer detection and monitoring, are gaining attention as vital diagnostic tools in oncology. As these countries ramp up their healthcare investments and address the rising cancer burden, the market is poised for substantial growth in both regions.
List of Key Companies Profiled
- Qiagen N.V
- Greiner Bio-One International GmbH
- Sysmex Corporation
- Miltenyi Biotech B.V & Co kg
- Bio-Techne Corporation
- Ikonisys, Inc.
- Menarini Silicon Biosystems SpA
- LungLife AI Inc.
- Aviva Systems Biology Corporation
- ScreenCell
Market Report Segmentation
By Product
- Kits & Reagents
- Devices
- Blood Collection Tubes
By End User
- Research and Academic Institutes
- Hospital & Clinics
- Diagnostic Centers
By Specimen
- Blood
- Bone Marrow
- Other Specimen
By Technology
- CTC Detection & Enrichment Methods
- CTC Analysis
- CTC Direct Detection
By Application
- Research, Clinical
- Drug/Therapy Development
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Circulating Tumor Cell Market by Product
Chapter 5. Asia Pacific Circulating Tumor Cell Market by End User
Chapter 6. Asia Pacific Circulating Tumor Cell Market by Specimen
Chapter 7. Asia Pacific Circulating Tumor Cell Market by Technology
Chapter 8. Asia Pacific Circulating Tumor Cell Market by Application
Chapter 9. Asia Pacific Circulating Tumor Cell Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Qiagen N.V
- Greiner Bio-One International GmbH
- Sysmex Corporation
- Miltenyi Biotech B.V & Co kg
- Bio-Techne Corporation
- Ikonisys, Inc.
- Menarini Silicon Biosystems SpA
- LungLife AI Inc.
- Aviva Systems Biology Corporation
- ScreenCell
Methodology
LOADING...
